Overview

High Potency Statins and Acute Kidney Injury

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
Statins are a class of cholesterol lowering medications that are prescribed for the prevention and treatment of cardiovascular disease. The purpose of this study is to determine if there is an excess risk of acute kidney injury (AKI) with high potency statins compared to low potency statins. The investigators will carry out separate population based cohort studies using administrative health care databases in nine jurisdictions in Canada, the US, and the UK. Cohorts will be defined by the initiation of a statin, with follow-up until hospitalization for AKI. Analyses will be done separately for groups of patients with and without chronic kidney disease. The results from the separate sites will be combined in a meta-analysis to provide an overall assessment of the risk of AKI in new statin users.
Details
Lead Sponsor:
Canadian Network for Observational Drug Effect Studies, CNODES
Collaborators:
Canadian Institutes of Health Research (CIHR)
Drug Safety and Effectiveness Network, Canada
Treatments:
Atorvastatin
Atorvastatin Calcium
Dihydromevinolin
Fluvastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
L 647318
Lovastatin
Pravastatin
Rosuvastatin Calcium
Simvastatin